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Original Articles
Prolonged Amenorrhea and Resumption
of Menses in Women with HIV
Helen E. Cejtin, MD,1 Charlesnika T. Evans, PhD, MPH,2 Ruth Greenblatt, MD,3
Howard Minkoff, MD,4 Kathleen M. Weber, MS,5 Rodney Wright, MD, MS,6
Christine Colie, MD,7 Elizabeth Golub, PhD, MPH,8 and L. Stewart Massad, MD9
Abstract
Objective: To compare etiologies of prolonged amenorrhea in a cohort of HIV-infected women with a cohort of
similar uninfected at-risk women.
Materials and Methods: Women from the Women’s Interagency HIV Study were seen every 6 months, and
completed surveys including questions about their menstruation. Those who reported no vaginal bleeding for at
least 1 year (‘‘prolonged amenorrhea’’) with subsequent resumption of bleeding were compared with women in
whom bleeding had stopped permanently (‘‘menopause’’). Characteristics associated with reversible prolonged
amenorrhea were ascertained.
Results: Of 828 women with prolonged amenorrhea, 37.6% had reversible amenorrhea and 62.4% never
resumed menses. HIV-seropositive women with prolonged amenorrhea were significantly younger at ces-
sation of menses than HIV-negative women ( p < 0.0001). Of those with reversible prolonged amenorrhea,
approximately half were taking medications associated with amenorrhea, including 95 (30.6%) hormonal
contraception, 80 (25.7%) opiates/stimulants, 16 (5.1%) psychotropic medications, and 6 (1.9%) chemo-
therapy. HIV-seropositive women were less likely to have medications as a cause of amenorrhea than
seronegative women ( p = 0.02). In multivariable analysis, women with reversible prolonged amenorrhea of
unknown etiology were younger ( p < 0.0001), more often obese ( p = 0.03), and less educated ( p = 0.01) than
those with permanent amenorrhea. Among HIV-seropositive women, markers of severe immunosuppression
were not associated with prolonged amenorrhea.
Conclusion: Women with HIV infection have unexplained prolonged amenorrhea more often than at-risk
seronegative women. This is especially common among obese, less-educated women. Prolonged amenorrhea in
the HIV-seropositive women should be evaluated and not be presumed to be to the result of menopause.
Keywords: HIV, amenorrhea, menopause, anovulation
Introduction
Potent antiretroviral therapies have resulted insignificantly increased survival of persons living with
HIV infection.1 Thus, increasingly, U.S. women with HIV
infection are aging2,3 and making the menopausal transition.
Although the number of women living with HIV infection
approaching menopause keeps increasing, there is a dearth
of research in this population.4
Research initially suggested that HIV infection was asso-
ciated with an earlier age of menopause than that seen in the
general population.5–8 However, subsequent research indicates
1Department of Obstetrics and Gynecology, John H. Stroger Jr. Hospital of Cook County, Feinberg School of Medicine, Northwestern
University, Chicago, Illinois.
2Department of Preventive Medicine and Center for Healthcare Studies Northwestern University and Department of Veterans Affairs,
Chicago, Illinois.
3Department of Clinical Pharmacy, University of California San Francisco, San Francisco, California.
4Department of Obstetrics and Gynecology, Maimonides Medical Center, New York, New York.
5Cook County Health and Hospitals System/Hektoen Institute of Medicine Chicago, Illinois.
6Department of Obstetrics and Gynecology, Albert Einstein College of Medicine, Bronx, New York.
7Department of Obstetrics and Gynecology, Georgetown University, District of Columbia, Washington.
8Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
9Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri.
JOURNAL OF WOMEN’S HEALTH
Volume 27, Number 12, 2018

















































that HIV infection itself may not be a major influence on age at
final menstrual period, with comorbid conditions such as illicit
substance and medication use contributing to the occurrence of
amenorrhea in HIV-infected women.9–11 Data on this topic,
however, are conflicting, with some studies showing an
earlier age of menopause in women who are HIV seropos-
itive, and others showing a similar age of last menstrual period
in seropositive women and in age, race, and socioeconomic
status-matched controls.12–14
Amenorrhea can result from chronic anovulation, uterine
factors such as Asherman’s syndrome, thyroid disease, ele-
vated prolactin from pituitary adenoma, pregnancy or lacta-
tion, or hormonal contraception.15 If it lasts 1 year or longer, a
woman may be mistakenly diagnosed as menopausal as per
the World Health Organization guidelines.16
There are many conditions that might disproportionately
affect HIV-infected women. Severe wasting from AIDS may
contribute to a hypothalamic cessation of menses.5 Anovulation
may result from opiate or antipsychotic use,17 cancer chemo-
therapy,18 use of hormones as an appetite stimulant,19 or even
emotional stress20 such as that associated with the initial diag-
nosis of HIV infection, stigma, and clinical disease progression.
Furthermore, protease inhibitor use has been associated with
insulin resistance21 and polycystic ovarian syndrome (PCOS) in
a single case report.22 Amenorrhea has even been reported in an
HIV-infected woman secondary to a cerebral toxoplasmosis
infection affecting production of gonadotropins.23
Although all these conditions may be more common among
women with HIV, their frequency in women with amenorrhea
is unclear. It is also unclear whether HIV itself might con-
tribute to a cessation of menses in the absence of severe im-
munosuppression or wasting, and by what mechanism.
The purpose of this study was to explore the potential
etiologies of prolonged amenorrhea in a population of HIV-
infected and demographically similar uninfected compari-
son women who are not menopausal. By looking at women
who have a resumption of menses after prolonged cessation,
we will be excluding menopause as a cause of amenorrhea.
Our hypothesis is that amenorrhea associated with HIV in-
fection is often secondary to comorbid conditions, and that
HIV may be independently associated with an increase in
prolonged amenorrhea that is reversible and not secondary
to menopause.
Materials and Methods
The Women’s Interagency HIV Study (WIHS) is an on-
going multicenter prospective cohort study of the natural
history of treated HIV infection in women in the United
States. WIHS enrollment began in 1994 at six study sites
(Bronx/Manhattan, Brooklyn, Chicago, Los Angeles, San
Francisco, and Washington DC), with expansions from
2001 to 2002 and from 2011 to 2012.
For the purpose of this study, to maximize follow-up, only
women from the original enrollment and first expansion
(including additional women from the original sites) were
included, comprising a total of 4,137 women (3,067 HIV
infected, 1,045 uninfected, and 25 seroconverted). Women
who converted from HIV negative to HIV seropositive
while in the study were excluded from this analysis. Study
methods and cohort characteristics have been described in
detail elsewhere.24,25 At each site, human subjects com-
mittees reviewed and approved the study, and all partici-
pants gave written informed consent.
Participants were seen approximately every 6 months,
at which time a physical examination was performed and self-
reported data were obtained using standardized survey instru-
ments administered by trained interviewers. Surveys included
questions about medical, surgical, and obstetrical history, use
of medications including antiretroviral therapy (ART), hor-
monal contraception, and prescription drugs, and use of illicit
drugs, alcohol, and tobacco as well as menstrual data.
HIV serology was performed at baseline and at each visit
on women with prior negative results. Among HIV-infected
women, quantification of HIV RNA and lymphocyte subsets
were measured semiannually using laboratories participating
in the NIAID Division of AIDS Virology and Immunology
Laboratory Quality Assurance Programs. Beginning in 2003,
many WIHS participants underwent anti-Müllerian hormone
(AMH) testing using a commercially available enzyme-linked
immunosorbent assay (Gen II; Beckman Coulter, Inc., Chaska,
MN) with a lower limit of detection 0.08 ng/mL as part of a
different investigation.26
Questions about menses included the date of last menstrual
period ad the presence of any vaginal bleeding in the previous
6 months. Prolonged amenorrhea was defined as at least three
consecutive visits without reported vaginal bleeding, or at
least 12 months of amenorrhea. Data were reported from
the index visit, defined as the first visit at which prolonged
amenorrhea was reported. Women who entered the WIHS
reporting amenorrhea were not counted as having prolonged
amenorrhea until this was reported at two consecutive visits.
They were considered to have resumption of menses if they
reported menses at any visit after having prolonged amenorrhea.
In an attempt to distinguish resumed menstruation from
pathologic sources of vaginal bleeding, women diagnosed
with cervical cancer or endometrial hyperplasia/cancer were
excluded from analysis. Likewise, to exclude menopause as a
cause of prolonged amenorrhea, those with an AMH level
FIG. 1. Women in the WIHS with amenorrhea. WIHS,
Women’s Interagency HIV Study.
























































(n = 517) p OR (95% CI) AOR (95% CI)
Frequency (%)
HIV seropositive 660 (79.7) 244 (78.5) 416 (80.5) 0.49 0.88 (0.63–1.25) 0.82 (0.56–1.20)
Age, years
<40 199 (24.0) 138 (44.4) 61 (11.8) <0.0001 Reference Reference
40–49 416 (50.2) 132 (42.4) 284 (54.9) 0.21 (0.14–0.30) 0.21 (0.14–0.30)
50+ 213 (25.7) 41 (13.2) 172 (33.3) 0.11 (0.07–0.17) 0.10 (0.07–0.16)
Age. mean (median) 44.7 (46.9) 40.5 (41.4) 47.2 (48.4) <0.0001a, <0.0001b
Race/ethnicity
White non-Hispanic 126 (15.2) 49 (15.8) 77 (14.9) 0.63 Reference
African American 224 (27.1) 89 (28.6) 135 (26.1) 1.04 (0.66–1.62)
White Hispanic 478 (57.7) 173 (55.6) 305 (59.0) 0.89 (0.60–1.33)
Parity, mean (range) 2.4 (2.0) 2.2 (2.0) 2.5 (2.0) 0.02a, 0.01b 0.91 (0.85–0.99)
Smoking status
Never 184 (22.2) 84 (27.0) 100 (19.3) 0.03 Reference
Current 442 (53.4) 158 (50.8) 284 (54.9) 0.66 (0.47–0.94)
Former 202 (24.4) 69 (22.2) 133 (25.7) 0.62 (0.41–0.93)
BMI
<18.5 36 (4.4) 9 (2.9) 27 (5.2) 0.39 0.59 (0.27–1.32)
18.5–24.9 270 (32.6) 97 (31.2) 173 (33.5) Reference
25–29.9 222 (26.8) 83 (26.7) 139 (26.9) 1.06 (0.74–1.54)
30+ 273 (33.0) 112 (36.0) 161 (31.1) 1.24 (0.88–1.75)
Missing 27 (3.3) 10 (3.2) 17 (3.3) 1.05 (0.46–2.38)
Education
Less than high school 311 (37.6) 134 (43.1) 177 (34.2) 0.04 Reference
High-school graduate 251 (30.3) 85 (27.3) 166 (32.1) 0.68 (0.48–0.95)
Some college or more 266 (32.1) 92 (29.6) 174 (33.7) 0.70 (0.50–0.98)
Income
£$6,000 168 (20.3) 72 (23.2) 96 (18.6) 0.38 Reference
$6,001–$12,000 308 (37.2) 107 (34.4) 201 (38.9) 0.71 (0.48–1.04)
$12,001–$18,000 112 (13.5) 42 (13.5) 70 (13.5) 0.80 (0.49–1.31)
$18,001+ 240 (29.0) 90 (28.9) 150 (29.0) 0.80 (0.54–1.20)
Hepatitis C positive (RNA
and AB positive)
255 (30.8) 86 (27.7) 169 (32.7) 0.13 0.79 (0.58–1.07)
HIV-positive women only
AOR (95% CI)c
n = 660 n = 244 n = 416 n = 459
HIV RNA detectable (n = 628) 369 (58.8) 137 (60.6) 232 (57.7) 0.48 1.13 (0.81–1.57)
Detectable HIV RNA (n = 367)
<4,000 167 (45.5) 54 (39.7) 113 (48.9) 0.02 Reference
4,001–20,000 74 (20.2) 36 (26.5) 38 (16.5) 1.98 (1.13–3.47)
20,001–100,000 70 (19.1) 31 (22.8) 39 (16.9) 1.66 (0.94–2.95)
>100,000 56 (15.3) 15 (11.0) 41 (17.8) 0.77 (0.39–1.50)
CD4 count (n = 633)
<200 125 (19.8) 41 (18.1) 84 (20.7) 0.72 Reference
200–499 265 (41.9) 96 (42.3) 169 (41.6) 1.16 (0.74–1.82)
500+ 243 (38.4) 90 (39.7) 153 (37.7) 1.21 (0.76–1.90)
Antiretroviral use since last visit 441 (66.8) 144 (59.0) 297 (71.4) 0.001 0.58 (0.41–0.80) 0.64 (0.45–0.92)
AIDS outcome 263 (39.9) 101 (41.4) 162 (38.9) 0.53 1.11 (0.80–1.53)
Women who never resume menses.
at-Test p-value.
bMedian two-sample test p-value.
cHIV-positive women only, AOR and 95% CIs are adjusted for BMI, age, education, and ART use.
AOR, adjusted odds ratio; ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval.















































that was below assay detection (<0.08 ng/mL) were excluded.
Women were censored from analysis at the time of a reported
pregnancy or lactation and if they had either their uterus or
one or both ovaries surgically removed. Women with several
episodes of prolonged amenorrhea were only included for the
first episode.
Statistics
Demographic and medical characteristics outlined pre-
viously were described by HIV status and reversible
amenorrhea using bivariate statistics including chi-square
test, unadjusted odds ratios (ORs), and 95% confidence in-
tervals (CIs) for categorical variables and t-test and median
two-sample tests for continuous variables. A multivariable
logistic model was fit to determine independent risk factors
associated with reversible amenorrhea in the WIHS cohort.
A separate model was fit for just HIV-infected women to test
the main hypothesis and determine whether specific HIV-
related factors and reversible causes were associated with
reversible amenorrhea.
Similar bivariate statistics and multivariable models were
used to assess factors associated with unexplained reversible
amenorrhea compared with women with permanent cessation
of menses. Bivariate statistics were also used to describe
etiology of amenorrhea by HIV status using chi-square tests.
All analyses were conducted using SAS software version 9.4
(SAS Institute, Inc., Cary, NC) and STATA 13.1 software
(StataCorp., College Station, TX).
Results
Of the 4,137 participants in the WIHS, only women with
available self-reported menstrual data across at least three
study visits and not meeting exclusion criteria were included
in this analysis. Of 1,152 women in the WIHS with available
data and reported amenorrhea for at least 1 year, 155 were
excluded for pregnancy or a history of hysterectomy or re-
moval of one or more adnexae, 168 were excluded for having
an undetectable AMH level (<0.08 ng/mL), and 1 was excluded
because we could not determine whether her intrauterine de-
vice was hormone secreting or not (Fig. 1).
There were 828 women included in the study met the def-
inition of prolonged amenorrhea. Of these, 517 (62.4%) did not
subsequently report vaginal bleeding during follow-up, and
were considered probably menopausal (63.0% of HIV-
positive, 60.1% HIV-negative women, NS). The mean age
of this group of women was 47.2 years overall, and was
significantly younger in the HIV-seropositive women (46.6
years) than in the HIV-negative women (49.6 years),
p < 0.0001.
The remaining 311 (37.6%) women subsequently reported
a resumption of menses at some time after 1 year, and they
were considered to have reversible prolonged amenorrhea
and not to be in menopause (Table 1). As expected, when
comparing women with prolonged amenorrhea that is re-
versible with those who never resumed bleeding again, those
with reversible amenorrhea were younger (mean age 40.5
years vs. 47.2 years, p < 0.0001). They also reported fewer
pregnancies in the past, were less likely to be current or
former tobacco users, and reported fewer years of education
than women who did not resume menstruation. In a multi-
variable model, only younger age remained a significant fac-
tor, where women with reversible amenorrhea were younger
than women without subsequent menses.
Among HIV-infected women who had prolonged amen-
orrhea (n = 660), indicators of HIV morbidity such as a his-
tory of CD4 lymphocyte count <200 or a history of clinical
AIDS were similar whether women resumed menses or not.
In a multivariable model controlled for age, body mass index
(BMI), years of education, and ART use, HIV-seropositive
women with reversible amenorrhea were younger (40–49
years, adjusted OR [AOR] = 0.26, 95% CI = 0.17–0.40,
p < 0.0001; 50+ years, AOR = 0.15, 95% CI = 0.09–0.26,
p < 0.0001 vs. <40 years) and less likely to be underweight
(AOR = 3.0, 95% CI = 0.11–0.82, p = 0.02), be a high school
graduate (AOR = 0.57, 95% CI = 0.38–0.87, p = 0.009), and
use ART (AOR = 0.64, 95% CI = 0.49–0.92, p = 0.001) than
women without subsequent menses.
Of the 311 women who resumed menses, the majority
(54.7%) had at least one known potential cause for cessation
of menses, and many (n = 33, 10.6%) reported multiple po-
tential causes for amenorrhea (Table 2). Hormonal







(n = 67) p
Frequency (%)
Any cause
Known 170 (54.7) 125 (51.2) 45 (67.2) 0.02
Unknown 141 (45.3) 119 (48.8) 22 (32.8)
No. of possible causesa
0 141 (45.3) 119 (48.8) 22 (32.8) Reference
1 137 (44.1) 104 (42.6) 33 (49.3) 0.08b
>1 33 (10.6) 21 (8.6) 12 (17.9) 0.007c
Hormonal contraception 95 (30.6) 72 (29.5) 23 (34.3) 0.45
Opiate/stimulant 80 (25.7) 53 (21.7) 27 (40.3) 0.002
Psychological medications 16 (5.1) 14 (5.7) 2 (3.0) 0.37
Cancer diagnosis 6 (1.9) 3 (1.2) 3 (4.5) 0.09
aGlobal chi-square p-value indicates there is a significant difference between HIV status and number of causes ( p = 0.02).
bCompares 0 versus 1 cause. No significant difference in 0 versus 1 cause by HIV status ( p = 0.08).
cCompares 0 versus 2 causes. Compared with having no causes, HIV-seronegative women were more likely to have more than 1 cause
( p = 0.007).

























































(n = 517) p OR (95% CI) AOR (95% CI)
Frequency (%)
HIV seropositive 535 (81.3) 119 (84.4) 416 (80.5) 0.29 1.31 (0.79–2.17) 1.44 (0.85–2.45)
Age, years
<40 95 (14.4) 34 (24.1) 61 (11.8) 0.0005 Reference Reference
40–49 358 (54.4) 74 (52.5) 284 (54.9) 0.47 (0.29–0.76) 0.47 (0.28–0.78)
50+ 205 (31.2) 33 (23.4) 172 (33.3) 0.34 (0.20–0.60) 0.32 (0.18–0.57)
Age, mean (median) 46.6 (48.1) 44.5 (45.8) 47.2 (48.4) <0.0001a, 0.003b
Race/ethnicity
White non-Hispanic 93 (14.1) 16 (11.4) 77 (14.9) 0.51 Reference
African American 176 (26.8) 41 (29.1) 135 (26.1) 1.46 (0.77–2.78)
White Hispanic 389 (59.1) 84 (59.6) 305 (59.0) 1.33 (0.73–2.39)
Parity, mean (range) 2.3 (2.0) 2.2 (2.0) 2.5 (2.0) 0.27a, 0.30b 0.95 (0.86–1.04)
Smoking status
Never 134 (20.4) 34 (24.1) 100 (19.3) 0.10 Reference
Current 347 (52.7) 63 (44.7) 284 (54.9) 0.65 (0.41–1.05)
Former 177 (26.9) 44 (31.2) 133 (25.7) 0.97 (0.58–1.63)
BMI
<18.5 30 (4.6) 3 (2.1) 27 (5.2) 0.03 0.55 (0.16–1.91) 0.44 (0.12–1.56)
18.5–24.9 208 (31.6) 35 (24.8) 173 (33.5) Reference Reference
25–29.9 175 (26.6) 36 (25.5) 139 (26.9) 1.28 (0.76–2.14) 1.28 (0.75–2.18)
30+ 224 (34.0) 63 (44.7) 161 (31.1) 1.93 (1.21–3.08) 2.20 (1.35–3.58)
Missing 21 (3.2) 4 (2.8) 17 (3.3) 1.06 (0.37–3.67) 1.18 (0.37–3.82)
Education
Less than high school 241 (36.6) 64 (45.4) 177 (34.2) 0.01 Reference Reference
High-school graduate 195 (29.6) 29 (20.6) 166 (32.1) 0.48 (0.30–0.79) 0.51 (0.31–0.84)
Some college or more 222 (33.7) 48 (34.0) 174 (33.7) 0.76 (0.50–1.17) 0.94 (0.60–1.47)
Income
£$6,000 124 (18.8) 28 (19.9) 96 (18.6) 0.69 Reference
$6,001–$12,000 250 (38.0) 49 (34.8) 201 (38.9) 0.84 (0.49–1.41)
$12,001–$18,000 87 (13.2) 17 (12.1) 70 (13.5) 0.83 (0.42–1.64)
$18,001+ 197 (29.9) 47 (33.3) 150 (29.0) 1.07 (0.63–1.83)
Hepatitis C positive (RNA
and AB positive)
211 (32.1) 42 (29.8) 169 (32.7) 0.51 0.87 (0.58–1.31)
HIV-positive women only
AOR (95% CI)cn = 535 n = 119 n = 416
HIV RNA detectable (n = 513) 293 (57.1) 61 (55.0) 232 (57.7) 0.60 0.89 (0.59–1.36)
HIV RNA (n = 292)
<4,000 142 (48.6) 29 (47.5) 113 (48.9) 0.22 Reference
4,001–20,000 51 (17.5) 13 (21.3) 38 (16.5) 1.33 (0.63–2.82)
20,001–100,000 53 (18.2) 14 (23.0) 39 (16.9) 1.40 (0.67–2.92)
>100,000 46 (15.8) 5 (8.2) 41 (17.8) 0.48 (0.17–1.31)
CD4 count (n = 516)
<200 106 (20.5) 22 (20.0) 84 (20.7) 0.91 Reference
200–499 213 (41.3) 44 (40.0) 169 (41.6) 0.99 (0.56–1.77)
500+ 197 (38.2) 44 (40.0) 153 (37.7) 1.10 (0.62–1.95)
Antiretroviral use since last visit 375 (70.1) 78 (65.6) 297 (71.4) 0.22 0.76 (0.49–1.18)
AIDS outcome 208 (38.9) 46 (38.7) 162 (38.9) 0.95 0.99 (0.65–1.50)
at-Test p-value.
bMedian two-sample test p-value.
cAOR and 95% CIs: None of the HIV variables were significant so were not included in the final model. The final model included age,
BMI category, and education status. Similar findings were seen in those who were HIV positive in terms of age, BMI, and education being
associated with amenorrhea status as seen in all women. (AOR for age, BMI, and education not shown).















































contraception was the most common, with 95 (30.6%) wo-
men reporting the use of oral or injectable hormones at the
index visit. The most common type of hormonal contracep-
tion used in those with prolonged amenorrhea was intra-
muscular depo-medroxyprogesterone acetate that was used in
72 (75.8%) of those women. The remaining 23 women in this
group (24.2%) used oral contraceptives. Of interest, four of
the women in the hormonal contraception group reported
previous surgical sterilization, and were likely using hor-
mones only to control bleeding or menopausal symptoms.
Other identifiable causes of reversible prolonged amen-
orrhea were opiate or stimulant use in 80 (25.7%), use of
psychiatric medications in 16 (5.1%), and a diagnosis of
cancer in 6 (1.9%). Of the cancers diagnosed, the majority
were lymphomas, with the remaining being cancers of the
lung, brain, breast, and thyroid. Amenorrhea in most of these
women was most likely a result of chemotherapy. There were
two women with thyroid cancer who most likely did not
receive chemotherapy, and so cancer was not included as a
possible etiology of their amenorrhea.
There were 141 women (45.3%) who had no identified
etiology of reversible prolonged amenorrhea. Almost half
of the HIV-infected women (48.8%) with prolonged
amenorrhea had no identifiable cause, compared with 32.8%
of seronegative women ( p = 0.02). Likewise, HIV-negative
women were significantly more likely (17.9%) than sero-
positive women (8.6%) to have multiple causes of amen-
orrhea ( p = 0.007).
When we compared women with unexplained revers-
ible amenorrhea with women without subsequent menses
(Table 3), the results were similar to Table 1. Women with
unexplained reversible amenorrhea were significantly youn-
ger ( p < 0.0001), more likely to be obese (AOR = 2.20, 95%
CI = 1.35–3.58), and less likely to have graduated from high
school (AOR = 0.51, 95% CI = 0.31–0.84). In a multivariable
model, all three associations persisted. Looking at HIV-
infected women, once again severity of HIV infection was
not associated with amenorrhea, and ART use was no longer
associated with sustained amenorrhea.
Discussion
HIV is an independent risk factor for prolonged amenor-
rhea that is not associated with medication or drug use, and
that may be misinterpreted as menopause. Amenorrhea has
been reported with the use of hormonal contraception,7,27,28
opiates and stimulants,29–34 antipsychotics,17 chemothera-
py,35 and even with emotional stress.36 In this study, pro-
longed amenorrhea over 1 year in duration associated with
the use of hormones, medications, and opiate or stimulant
use is commonly seen in both HIV-infected women and so-
ciodemographically similar uninfected women. As recreational
drug use, mental illness, and stress are more common in women
living with HIV infection,17,37,38 this is a group more likely to
experience prolonged amenorrhea as a result of these factors.
Among women without these causes, prolonged amenor-
rhea is associated with younger age, higher BMI, and less
education than seen in counterparts who do not resume
menses. The association between amenorrhea and less edu-
cation is difficult to explain biologically. There are reports in
the literature including a large meta-analysis demonstrating an
association between menopause and decreased socioeconomic
status in general and level of education more specifically.39
Whether this is because of the association between adverse
childhood events and both low level of education and early
timing of menopause has been proposed.40,41 The association
of amenorrhea with high BMI suggests that many women in
our study with reversible amenorrhea have anovulation that is
related to obesity such as that seen with PCOS.
The results of this study show that seropositive women
often have prolonged reversible amenorrhea for a variety of
reasons, and previous reports of an earlier age of menopause
in women with HIV infection may have reflected inclusion of
women with prolonged but reversible amenorrhea.29,42,43 We
previously demonstrated that the median age at cessation of
menses was 47 years in the WIHS cohort, but when follicle-
stimulating hormone (FSH) was analyzed, approximately
half of the HIV-infected nonmenstruating women did not
have a level consistent with menopause.9
The majority of seropositive women in this study (65.6%)
are on ART, and the severity of HIV disease is not associated
with amenorrhea, suggesting that HIV does not often induce
hypothalamic amenorrhea through wasting. HIV-seropositive
women have an increase in insulin resistance/diabetes and a
50% increase in the metabolic syndrome, with older age,
higher BMI, and tobacco use all being risk factors.21,44 PCOS
with amenorrhea and obesity are frequently associated with the
metabolic syndrome. Thus, it is possible that the prolonged
reversible amenorrhea in HIV-infected women who are obese
is from chronic anovulation.
It is unclear from our study whether stress plays a role in
amenorrhea, but a very high prevalence of significant stress
and abuse was noted in the WIHS cohort.38 AMH levels are
directly associated with antral follicle count, and thus are de-
creased with menopause and increased with PCOS.45 Studies
have demonstrated that AMH levels are not related to BMI, but
are reflective of insulin resistance.46 AMH level was found to
be useful in predicting the age at menopause in HIV-infected
women,47 and when analyzed in a group of women from the
WIHS cohort, amenorrhea was associated with a 20%–25%
increase in AMH.26 Thus, the increased AMH seen in HIV-
infected women with amenorrhea may be related to chronic
anovulation mediated by high levels of obesity and the stress
and insulin resistance associated with HIV infection.
Limitations of this study include lack of information
on other potential causes of amenorrhea, such as thyroid dis-
ease, disorders of prolactin secretion, and hypothalamic eti-
ologies, and information about comorbidities such as diabetes
and renal disease. It is unclear whether the women who never
resume menses are all postmenopausal, and some may have
chronic diseases associated with anovulation such as hypo-
thalamic hypogonadotropism. Menstrual data and substance
use information are only based on self-report. The strengths are
the large sample size and the longitudinal database spanning
over 20 years. Areas for future research include evaluating
women in the WIHS with prolonged amenorrhea for level of
stress and markers of chronic anovulation, such as the presence
of multiple follicles on ultrasound, and ruling out thyroid dis-
ease and disorders of prolactin secretion in this group.
Conclusions
It is very important to understand whether the etiology of
prolonged amenorrhea is menopause in the HIV-infected















































women, in whom reversible amenorrhea is common. With an
increase in diseases of bone mineral density and coronary
artery disease associated with HIV infection,48 menopause
represents a time when diagnosis and active management
of these associated conditions is crucial, especially in cases
of early ovarian insufficiency. If amenorrhea is indeed as-
sociated with chronic anovulation, contraceptive needs
should be addressed and endometrial evaluation and active
management to prevent endometrial hyperplasia/cancer is
essential.49 Liberal use of serum FSH and AMH levels and
ultrasound can help determine if such a woman is meno-
pausal or in a chronic anovulatory state. Prolonged amen-
orrhea in the HIV-infected women should never be ignored
or assumed to be menopause.
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